Combination of glibenclamide–metformin HCl for the treatment of type 2 diabetes mellitus

Bibliography

• National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the united states, 2011 [Internet]. 2011. Available from: http://www.cdc.gov/diabetes/pubs/factsheet11.htm
   Google Scholar
• Turner R, Homan R, Cull A. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet 1998;352(9131):837-53
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2011. Diabetes Care 2011;34(Suppl 1):S11-61
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, Management of hyperglycemia in type 2 diabetes: a patient-centered approach: Position statement of the american diabetes association (ADA) and the european association for the study of diabetes (EASD). Diabetes Care 2012;35(6):1364-79
   PubMed Web of Science ®Google Scholar
• Matthews DR, Cull CA, Stratton IM, UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK prospective diabetes study (UKPDS) group. Diabet Med 1998;15(4):297-303
   PubMed Web of Science ®Google Scholar
• Luzi L, Pozza G. Glibenclamide: an old drug with a novel mechanism of action? Acta Diabetol 1997;34(4):239-44
   PubMed Web of Science ®Google Scholar
• Lopez-Alarcon L, Munoz-Alonso MJ, Guijarro C, Feliu JE. Modulation of glycogen phosphorylase activity and fructose 2,6-bisphosphate levels by glibenclamide and meglitinide in isolated rat hepatocytes: a comparative study. Metabolism 1995;44(8):1000-7
   PubMedGoogle Scholar
• Stumvoll M, Nurjhan N, Perriello G, Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;Aug31333(9):550-4
   PubMed Web of Science ®Google Scholar
• He L, Sabet A, Djedjos S, Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009;137(4):635-46
   PubMed Web of Science ®Google Scholar
• Cho YM, Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 2011;54(2):219-22
   PubMedGoogle Scholar
• Glucovance [Internet]. Princeton, NJ: Bristol-Myers Squibb, Inc. 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021178s012lbl.pdf
   Google Scholar
• Kasim NA, Whitehouse M, Ramachandran C, Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004;1(1):85-96
   PubMed Web of Science ®Google Scholar
• Balant L, Zahnd G, Gorgia A, Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 1973;331-8
   PubMed Web of Science ®Google Scholar
• Neugebauer G, Betzien G, Hrstka V, Absolute bioavailability and bioequivalence of glibenclamide (semi-euglucon N). Int J Clin Pharmacol Ther Toxicol 1985;23(9):453-60
   PubMedGoogle Scholar
• Feldman JM. Glyburide: a second-generation sulfonylurea hypoglycemic agent. history, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects. Pharmacotherapy 1985;5(2):43-62
   PubMedGoogle Scholar
• Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994;17(9):1026-30
   PubMedGoogle Scholar
• Rydberg T, Jonsson A, Karlsson MO, Melander A. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1997;43(4):373-81
   PubMedGoogle Scholar
• Cheng CL, Yu LX, Lee HL, Biowaiver extension potential to BCS class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur J Pharm Sci 2004;22(4):297-304
   PubMed Web of Science ®Google Scholar
• Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999;20(6):489-503
   PubMed Web of Science ®Google Scholar
• Garber AJ, Duncan TG, Goodman AM, Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103(6):491-7
   PubMed Web of Science ®Google Scholar
• Glucophage [Internet]. Princeton, NJ: Bristol-Myers Squibb, Inc. 2009. Available from: http://www.fda.gov/ohrms/dockets/dailys/02/May02/053102/800471e6.pdf
   Google Scholar
• Scheen AJ, Jaminet C, Luyckx AS, Lefebvre PJ. Pharmacokinetics and pharmacological properties of two galenical preparations of glibenclamide, HB419 and HB420, in non insulin-dependent (type 2) diabetes. Int J Clin Pharmacol Ther Toxicol 1987;25(2):70-6
   PubMedGoogle Scholar
• Flores-Murrieta FJ, Aguilar-Cota ME, Camacho A, Comparative bioavailability of two oral formulations manufactured in mexico containing glyburide and metformin in diabetic patients. Proc West Pharmacol Soc 2003;46:82-4
   PubMedGoogle Scholar
• Donahue SR, Turner KC, Patel S. Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes. Clin Pharmacokinet 2002;41(15):1301-9
   PubMedGoogle Scholar
• Marathe PH, Arnold ME, Meeker J, Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. J Clin Pharmacol 2000;40(12 Pt 2):1494-502
   PubMedGoogle Scholar
• Timmins P, PMarathe PH, Cave G, Development of a glyburide-metformin fixed comnination tablet with optimized glyburide particle size. Drug Dev Res 2006;66:25-35
   Google Scholar
• Blonde L, Rosenstock J, Mooradian AD, Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab 2002;4(6):368-75
   PubMedGoogle Scholar
• Garber AJ, Donovan DS Jr, Dandona P, Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003;88(8):3598-604
   PubMedGoogle Scholar
• DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. the multicenter metformin study group. N Engl J Med 1995;333(9):541-9
   PubMed Web of Science ®Google Scholar
• Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (glucovance) in type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002;19(8):673-80
   PubMedGoogle Scholar
• Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23(5):611-14
   PubMed Web of Science ®Google Scholar
• Blonde L, Wogen J, Kreilick C, Seymour AA. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003;5(6):424-31
   PubMedGoogle Scholar
• Melikian C, White TJ, Vanderplas A, Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24(3):460-7
   PubMed Web of Science ®Google Scholar
• Lim PC, Lim SL, Oiyammaal C. Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus. Med J Malaysia 2012;67(1):21-4
   PubMedGoogle Scholar
• Cabrieres L, Roze S, Comte S, Cost-effectiveness of switching patients to combined glyburide and metformin (glucovance) when poorly controlled with metformin monotherapy: A french analysis. 38th Annual Meeting of the EASD; Budapest, Hungary. 2002. p. 0930
   Google Scholar
• Cugnardey N, Roze S, Palmer A, Fixed combination metformin plus glibenclamide (glucovnace) is cost and life saving compared to metformin plus rosiglitazone in type 2 diabetes patients in france. ISPOR 8th Annual European Congress; Florence, Italy. 2005. p. PDB25
   Google Scholar
• Duckworth W, Marcelli M, Padden M, Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. J Manag Care Pharm 2003;9(3):256-62
   PubMedGoogle Scholar
• Dailey GE III, Noor MA, Park JS, Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 2004;116(4):223-9
   PubMed Web of Science ®Google Scholar
• De Mattia G, Laurenti O, Moretti A. Comparison of glycaemic control in patients with type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study. Acta Diabetol 2009;46(1):67-73
   PubMedGoogle Scholar
• van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50(6):735-41
   PubMed Web of Science ®Google Scholar
• Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003;88(2):531-7
   PubMed Web of Science ®Google Scholar
• Mocanu MM, Maddock HL, Baxter GF, Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001;103(25):3111-16
   PubMedGoogle Scholar
• Flynn DM, Smith AH, Treadway JL, The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits. Cardiovasc Drugs Ther 2005;19(5):337-46
   PubMedGoogle Scholar
• Fisman EZ, Tenenbaum A, Boyko V, Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001;24(2):151-8
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meininger G, Sheng D, Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9(2):194-205
   PubMed Web of Science ®Google Scholar
• Seck T, Nauck M, Sheng D, Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010;64(5):562-76
   PubMed Web of Science ®Google Scholar
• Goke B, Gallwitz B, Eriksson J, D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010;64(12):1619-31
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Charpentier G, Ostgren CJ, Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26(7):540-9
   PubMed Web of Science ®Google Scholar
• Bennett WL, Maruthur NM, Singh S, Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154(9):602-13
   PubMed Web of Science ®Google Scholar
• Frederich R, Alexander JH, Fiedorek FT, A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122(3):16-27
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J 2011;162(5):818-825.e6
   PubMed Web of Science ®Google Scholar
• Sitagliptin cardiovascular outcome study (0431-082 AMI) (TECOS) [Internet]. 2012; Available from. http://clinicaltrials.gov/ct2/show/NCT00790205?term=TECOS&rank=1
   Google Scholar
• Cardiovascular outcomes study of alogliptin in subjects with type 2 diabetes and acute coronary syndrome (EXAMINE) [Internet]. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT00968708?term=EXAMINE&rank=1
   Google Scholar